Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Payables (2018 - 2025)

BioNexus Gene Lab's Payables history spans 8 years, with the latest figure at $375380.0 for Q3 2025.

  • For Q3 2025, Payables rose 28.5% year-over-year to $375380.0; the TTM value through Sep 2025 reached $375380.0, up 28.5%, while the annual FY2024 figure was $1.5 million, 730.97% up from the prior year.
  • Payables for Q3 2025 was $375380.0 at BioNexus Gene Lab, up from $307340.0 in the prior quarter.
  • Across five years, Payables topped out at $1.8 million in Q2 2023 and bottomed at $29776.0 in Q3 2023.
  • The 5-year median for Payables is $169883.0 (2024), against an average of $437618.6.
  • The largest annual shift saw Payables soared 5562.07% in 2023 before it crashed 90.68% in 2024.
  • A 5-year view of Payables shows it stood at $71814.0 in 2021, then soared by 43.94% to $103370.0 in 2022, then soared by 75.01% to $180912.0 in 2023, then surged by 730.97% to $1.5 million in 2024, then plummeted by 75.03% to $375380.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Payables are $375380.0 (Q3 2025), $307340.0 (Q2 2025), and $287189.0 (Q1 2025).